Korean Circ J.  2020 Oct;50(10):845-866. 10.4070/kcj.2020.0196.

2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction

  • 1Department of Internal Medicine, Chosun University College of Medicine, Gwangju, Korea
  • 2Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea
  • 3Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
  • 4Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon, Korea
  • 5Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  • 6Division of Cardiology, Department of Internal Medicine and Cardiovascular Centre, Seoul National University Hospital, Seoul, Korea
  • 7Division of Cardiovascular, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University, Seoul, Korea
  • 8Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju, Korea
  • 9Cardiology Division, Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Korea
  • 10Cardiovascular Center, Kyung Hee University Hospital at Gangdong, Seoul, Korea
  • 11Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea
  • 12School of Medicine, Kyungpook National University, Daegu, Korea


Clinical practice guidelines published by the European Society of Cardiology and the American College of Cardiology/American Heart Association summarize the available evidence and provide recommendations for health professionals to enable appropriate clinical decisions and improve clinical outcomes for patients with acute myocardial infarction (AMI). However, most current guidelines are based on studies in non-Asian populations in the pre-percutaneous coronary intervention (PCI) era. The Korea Acute Myocardial Infarction Registry is the first nationwide registry to document many aspects of AMI from baseline characteristics to treatment strategies. There are well-organized ongoing and published randomized control trials especially for antiplatelet therapy among Korean patients with AMI. Here, members of the Task Force of the Korean Society of Myocardial Infarction review recent published studies during the current PCI era, and have summarized the expert consensus for the pharmacotherapy of AMI.


Myocardial infarction; Drug therapy
Full Text Links
  • KCJ
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr